Top Markets
#1 DogBull DogBull +54.40%
#2 Siren Siren +31.81%
#3 OriginTrail OriginTrail +15.19%
#4 Verus Coin Verus Coin +11.30%
#5 Tutorial Tutorial +8.83%
#6 Yield Basis Yield Basis +8.48%
#7 Prom Prom +8.33%
#8 Falcon Finance Falcon Finance +7.80%
#9 COTI COTI +7.42%
#10 Stargate Finance Stargate Finance +6.97%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
ABIONYX Pharma S.A. ABIONYX Pharma S.A.

ABIONYX Pharma S.A.

ABNX
Rank in Stocks #21916
ABIONYX Pharma SA is a biotechnology company dedicated to the identification... ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.
Share Price
$2.32
Last synced: 2026-08-21
Market Cap
$98.03M
Change (1 day)
-1.91%
Change (1 year)
-5.84%
Country
FR
Trade ABIONYX Pharma S.A. (ABNX)

Category

Healthcare
P/E ratio for ABIONYX Pharma S.A. (ABNX)
P/E ratio as of 2026 TTM: 0
According to ABIONYX Pharma S.A. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for ABIONYX Pharma S.A. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.